AIM ImmunoTech Inc. (AIM) SEC filings

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$0.15+0.00 (+0.13%)

Close on Nov 12, 2026Market cap $4.52MP/E –Yield –

SEC filings

40 of AIM ImmunoTech's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	Sep 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 14, 2026	SEC EDGAR
Current report	8-K	Sep 3, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Aug 31, 2026	Sep 4, 2026	SEC EDGAR
Current report	8-K	Aug 11, 2026	Aug 11, 2026	SEC EDGAR
Current report	8-K	Aug 7, 2026	Aug 10, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Jul 31, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jul 31, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jul 15, 2026	Jul 16, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2026	Jun 25, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 15, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 11, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 10, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 21, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 19, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Apr 10, 2026	Apr 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 27, 2026	SEC EDGAR
Current report	8-K	Mar 4, 2026	Mar 6, 2026	SEC EDGAR
Current report	8-K	Feb 5, 2026	Feb 5, 2026	SEC EDGAR
Current report	8-K	Jan 20, 2026	Jan 20, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 16, 2025	Dec 17, 2025	SEC EDGAR
Current report	8-K	Nov 18, 2025	Nov 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 17, 2025	SEC EDGAR
Current report	8-K	Oct 29, 2025	Oct 29, 2025	SEC EDGAR
Proxy statement	DEF 14A	Oct 29, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Oct 20, 2025	Oct 20, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jul 30, 2025	Jul 31, 2025	SEC EDGAR
Current report	8-K	Jul 28, 2025	Jul 28, 2025	SEC EDGAR
Current report	8-K	Jun 17, 2025	Jun 20, 2025	SEC EDGAR
Current report	8-K	May 29, 2025	Jun 12, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in AIM ImmunoTech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jun 12, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AIM.

Compare: AIM vs INMB · AIM vs ABPO · AIM vs ARTV · AIM vs ATYR · AIM vs HIND

Company	Revenue	Growth
HIND	$153.10K	-55.6%
AIM	$91.00K	-18.8%
INMB	–	–
ABPO	–	–
ARTV	–	–
ATYR	–	–

Company

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Held by institutions: 3.8%
Auditor: BDO USA, P.C.
SEC CIK: 946644

Advertisement
300 × 250

See a number that looks wrong?